"The Company intends to confirm the effectiveness of the drug against HBsAg clearance and its effect on the viral load, as well as demonstrate good tolerability and safety of the drug in the target population of patient".It is expected that the results of the study, which was launched in Russia in the largest specialized centers, will be available by the end of 2013.
欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) | Powered by Discuz! X1.5 |